1119 related articles for article (PubMed ID: 26774508)
21. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.
Agarwal N; McQuarrie K; Bjartell A; Chowdhury S; Pereira de Santana Gomes AJ; Chung BH; Özgüroğlu M; Juárez Soto Á; Merseburger AS; Uemura H; Ye D; Given R; Cella D; Basch E; Miladinovic B; Dearden L; Deprince K; Naini V; Lopez-Gitlitz A; Chi KN;
Lancet Oncol; 2019 Nov; 20(11):1518-1530. PubMed ID: 31578173
[TBL] [Abstract][Full Text] [Related]
22. Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: the OCUU-CRPC study.
Iguchi T; Tamada S; Kato M; Yasuda S; Machida Y; Ohmachi T; Ishii K; Iwata H; Yamamoto S; Kanamaru T; Morimoto K; Hase T; Tashiro K; Harimoto K; Deguchi T; Adachi T; Iwamoto K; Takegaki Y; Nakatani T
Int J Clin Oncol; 2020 Mar; 25(3):486-494. PubMed ID: 31564004
[TBL] [Abstract][Full Text] [Related]
23. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
24. Increased survival with enzalutamide in prostate cancer after chemotherapy.
Scher HI; Fizazi K; Saad F; Taplin ME; Sternberg CN; Miller K; de Wit R; Mulders P; Chi KN; Shore ND; Armstrong AJ; Flaig TW; Fléchon A; Mainwaring P; Fleming M; Hainsworth JD; Hirmand M; Selby B; Seely L; de Bono JS;
N Engl J Med; 2012 Sep; 367(13):1187-97. PubMed ID: 22894553
[TBL] [Abstract][Full Text] [Related]
25. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.
Hussain M; Fizazi K; Saad F; Rathenborg P; Shore N; Ferreira U; Ivashchenko P; Demirhan E; Modelska K; Phung D; Krivoshik A; Sternberg CN
N Engl J Med; 2018 Jun; 378(26):2465-2474. PubMed ID: 29949494
[TBL] [Abstract][Full Text] [Related]
26. Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study).
Iguchi T; Tamada S; Kato M; Yasuda S; Yamasaki T; Nakatani T
BMC Cancer; 2019 Apr; 19(1):339. PubMed ID: 30971225
[TBL] [Abstract][Full Text] [Related]
27. Determination of enzalutamide long-term safety and efficacy for castration-resistant prostate cancer patients after combined anti-androgen blockade followed by alternative anti-androgen therapy: a multicenter prospective DELC study.
Nagahara A; Uemura M; Sato M; Nakata W; Tsujihata M; Takao T; Matsumura S; Nishimura K; Takada S; Iwanishi T; Kobayashi Y; Ishizuya Y; Takada T; Okada K; Inoue H; Kato T; Hatano K; Kawashima A; Ujike T; Fujita K; Nonomura N
Jpn J Clin Oncol; 2024 May; 54(5):584-591. PubMed ID: 38305451
[TBL] [Abstract][Full Text] [Related]
28. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.
Saad F; Fizazi K; Jinga V; Efstathiou E; Fong PC; Hart LL; Jones R; McDermott R; Wirth M; Suzuki K; MacLean DB; Wang L; Akaza H; Nelson J; Scher HI; Dreicer R; Webb IJ; de Wit R;
Lancet Oncol; 2015 Mar; 16(3):338-48. PubMed ID: 25701170
[TBL] [Abstract][Full Text] [Related]
29. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
Smith M; Parker C; Saad F; Miller K; Tombal B; Ng QS; Boegemann M; Matveev V; Piulats JM; Zucca LE; Karyakin O; Kimura G; Matsubara N; Nahas WC; Nolè F; Rosenbaum E; Heidenreich A; Kakehi Y; Zhang A; Krissel H; Teufel M; Shen J; Wagner V; Higano C
Lancet Oncol; 2019 Mar; 20(3):408-419. PubMed ID: 30738780
[TBL] [Abstract][Full Text] [Related]
30. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.
Armstrong AJ; Szmulewitz RZ; Petrylak DP; Holzbeierlein J; Villers A; Azad A; Alcaraz A; Alekseev B; Iguchi T; Shore ND; Rosbrook B; Sugg J; Baron B; Chen L; Stenzl A
J Clin Oncol; 2019 Nov; 37(32):2974-2986. PubMed ID: 31329516
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL.
Graff JN; Baciarello G; Armstrong AJ; Higano CS; Iversen P; Flaig TW; Forer D; Parli T; Phung D; Tombal B; Beer TM; Sternberg CN
Ann Oncol; 2016 Feb; 27(2):286-94. PubMed ID: 26578735
[TBL] [Abstract][Full Text] [Related]
32. Enzalutamide in metastatic prostate cancer before chemotherapy.
Beer TM; Armstrong AJ; Rathkopf DE; Loriot Y; Sternberg CN; Higano CS; Iversen P; Bhattacharya S; Carles J; Chowdhury S; Davis ID; de Bono JS; Evans CP; Fizazi K; Joshua AM; Kim CS; Kimura G; Mainwaring P; Mansbach H; Miller K; Noonberg SB; Perabo F; Phung D; Saad F; Scher HI; Taplin ME; Venner PM; Tombal B;
N Engl J Med; 2014 Jul; 371(5):424-33. PubMed ID: 24881730
[TBL] [Abstract][Full Text] [Related]
33. Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.
Sternberg CN; Fizazi K; Saad F; Shore ND; De Giorgi U; Penson DF; Ferreira U; Efstathiou E; Madziarska K; Kolinsky MP; Cubero DIG; Noerby B; Zohren F; Lin X; Modelska K; Sugg J; Steinberg J; Hussain M;
N Engl J Med; 2020 Jun; 382(23):2197-2206. PubMed ID: 32469184
[TBL] [Abstract][Full Text] [Related]
34. Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer.
Kim CS; Choi YD; Lee SE; Lee HM; Ueda T; Yonese J; Fukagai T; Chiong E; Lau W; Abhyankar S; Theeuwes A; Tombal B; Beer TM; Kimura G
Medicine (Baltimore); 2017 Jul; 96(27):e7223. PubMed ID: 28682871
[TBL] [Abstract][Full Text] [Related]
35. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
Kunath F; Grobe HR; Rücker G; Motschall E; Antes G; Dahm P; Wullich B; Meerpohl JJ
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009266. PubMed ID: 24979481
[TBL] [Abstract][Full Text] [Related]
36. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.
Fizazi K; Tran N; Fein L; Matsubara N; Rodriguez-Antolin A; Alekseev BY; Özgüroğlu M; Ye D; Feyerabend S; Protheroe A; Sulur G; Luna Y; Li S; Mundle S; Chi KN
Lancet Oncol; 2019 May; 20(5):686-700. PubMed ID: 30987939
[TBL] [Abstract][Full Text] [Related]
37. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
Attard G; Murphy L; Clarke NW; Sachdeva A; Jones C; Hoyle A; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Gilson C; Rush H; Abdel-Aty H; Amos CL; Murphy C; Chowdhury S; Malik Z; Russell JM; Parkar N; Pugh C; Diaz-Montana C; Pezaro C; Grant W; Saxby H; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzouebi M; Parikh O; Robinson A; Montazeri AH; Wylie J; Zarkar A; Cathomas R; Brown MD; Jain Y; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
Lancet Oncol; 2023 May; 24(5):443-456. PubMed ID: 37142371
[TBL] [Abstract][Full Text] [Related]
38. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
Fallah J; Zhang L; Amatya A; Gong Y; King-Kallimanis B; Bhatnagar V; Weinstock C; Suzman DL; Agrawal S; Chang E; Anscher MS; Chi DC; Xu JX; Brewer JR; Brave MH; Hadadi M; Theoret MR; Kluetz PG; Goldberg KB; Ibrahim A; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L; Singh H
Lancet Oncol; 2021 Sep; 22(9):1230-1239. PubMed ID: 34310904
[TBL] [Abstract][Full Text] [Related]
39. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.
Beer TM; Armstrong AJ; Rathkopf D; Loriot Y; Sternberg CN; Higano CS; Iversen P; Evans CP; Kim CS; Kimura G; Miller K; Saad F; Bjartell AS; Borre M; Mulders P; Tammela TL; Parli T; Sari S; van Os S; Theeuwes A; Tombal B
Eur Urol; 2017 Feb; 71(2):151-154. PubMed ID: 27477525
[TBL] [Abstract][Full Text] [Related]
40. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
Fizazi K; Massard C; Bono P; Jones R; Kataja V; James N; Garcia JA; Protheroe A; Tammela TL; Elliott T; Mattila L; Aspegren J; Vuorela A; Langmuir P; Mustonen M;
Lancet Oncol; 2014 Aug; 15(9):975-85. PubMed ID: 24974051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]